GLPwatch
Web Exclusive. Annals On Call - Dulaglutide, Semaglutide, and Tirzepatide: How Do Gastrointestinal Adverse Effects Compare?
Ann Intern Med · 2026
Last updated 2026-05-28| Journal | Ann Intern Med, 2026 |
|---|---|
| Citations | 0 |
| Molecules | semaglutide, tirzepatide, dulaglutide |
Full record and abstract on PubMed 41554140 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Tirzepatide Once Weekly for the Treatment of Obesity.
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.